Generalized Myasthenia Gravis, also known as gMG, is a rare autoimmune disease that impacts the neuromuscular system. gMG symptoms can have an immense impact on a patient’s life. Jan was enjoying retirement in Florida with her husband when she abruptly began experiencing symptoms that ultimately led to her being diagnosed with anti-acetylcholine receptor (AChR) antibody positive gMG. After discussing all of the treatment options, Jan and her neurologist decided that ULTOMIRIS® (ravulizumab-cwvz) would be a good fit for her. Special thanks to Alexion Pharmaceuticals, Inc. for their sponsorship of this program. IMPORTANT SAFETY INFORMATION FOR ULTOMIRIS (injection for intravenous use, 300 mg/ 3mL vial) What is the most important information I should know about ULTOMIRIS? ULTOMIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections. • ULTOMIRIS increases your chance of getting serious meningococcal infections that may quickly become life-threatening or cause death if not recognized and treated early. You must complete or update meningococcal vaccine(s) at least 2 weeks before your first dose of ULTOMIRIS. If you have not completed your meningococcal vaccines and ULTOMIRIS must be started right away, you should receive the required vaccine(s) as soon